Aaron Abend’s Post

Now available! NEW Rheum2Learn 2.0 modules—Systemic Sclerosis and Sjögren’s Disease. These complimentary Rheum2Learn 2.0 activities provide fundamental rheumatology education and include 3 clinical cases. Explore → https://acr.tw/47lLGHQ

Now available! NEW Rheum2Learn 2.0 modules—Systemic Sclerosis and Sjögren’s Disease. These complimentary Rheum2Learn 2.0 activities provide fundamental rheumatology education and include 3 clinical cases. Explore → https://acr.tw/47lLGHQ

Now available! NEW Rheum2Learn 2.0 modules—Systemic Sclerosis and Sjögren’s Disease. These complimentary Rheum2Learn 2.0 activities provide fundamental rheumatology education and include 3 clinical cases. Explore → https://acr.tw/47lLGHQ

Important step to fully understand the current knowledge on the utility of PR3-ANCA (anti-PR3 antibodies) as a novel biomarker in #inflammatoryboweldisease for diagnostic, prognostic and theranostic purposes, and continue moving it forward towards the lab, the clinic, and to improve patient care. Great job, CARMEN ANDALUCIA PINTADO! #autoimmunity #ibd #precisionmedicine #autoimmunediseases #biomarkers #autoantibodies

"For example, as a Phase 2 participant, I endured a battery of tests — yet as a patient with Fabry disease, one of the main issues I struggle with is fatigue, and fatigue sometimes leads to a pain crisis. This made it very difficult to adhere to the back-to-back timing of the tests." There's a lot of great (and important) insight in this article to better understand clinical trials from the patient perspective. Shout out to Sabina Kineen for sharing her clinical trial experience! https://lnkd.in/g8NR2eVD

Rare Disease Show: Episode 3 Understanding Thallasemia with Dr Anupam Sachdeva Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are medical conditions that affect only a small percentage of the population. Throughout this series, we'll discuss these rare diseases in various episodes, with medical experts providing clear explanations and insights. Rare Disease Show Episode 3 ANUPAM SACHDEVA For more information click on the link below:

Let's explore the efficacy of granulomonocytapheresis as a non-pharmacologic treatment for Inflammatory Bowel Disease. This review is a significant contribution to the field, covering a broad age range and diverse disease profiles. 🌐 As healthcare professionals, it's crucial to stay informed about innovative treatment methods. This research offers valuable insights into alternative approaches for managing complex conditions. 📚 Read the full study and stay ahead in the evolving landscape of medical science: https://bit.ly/3NUwbjb #InflammatoryBowelDisease #MedicalResearch #HealthcareInnovation #CureusJournal

For many people with sickle cell disease, treatment through clinical trials provides hope and a potential cure. But they’re not always easy to find or understand. Our Clinical Trials Search and Support team makes it easy for providers and patients to find clinical trials and connect with trial sites. Search for sickle cell disease trials: https://bit.ly/450D5t5 #BeTheMatch #SickleCellAwarenessMonth #SickleCellDisease #ClinicalTrials

 This study could be useful to guide and inform clinical research on the most urgent area of impact of ETI on CF lung disease and its clinical management  https://lnkd.in/dXsn3Ecb 

November is American Diabetes Month – did you know that around one third of adults over 40 with diabetes have diabetic eye disease? These ophthalmic conditions, including diabetic retinopathy, are progressive – patients face a substantial risk for blindness as time goes on, and the current standard of care is to “watch and wait” until vision is impacted. OcuTerra is working to enable earlier, non-invasive treatment for DR by developing OTT166 eye drops, currently under evaluation in the Phase 2 DR:EAM clinical trial. Learn more about the ongoing DR:EAM study: https://lnkd.in/djh-NbZQ